Samsung Biologics achieves top ESG risk rating from Sustainalytics

Samsung Biologics has earned the highest possible rating, “Negligible,” in the 2026 ESG Risk Rating issued by Sustainalytics. The company achieved a score of 9, an improvement from its previous “Low Risk” status. Out of 842 companies in the global pharmaceutical industry, Samsung Biologics ranked fourth, placing it within the top 0.5 percent of its sector.

The evaluation by Sustainalytics, a subsidiary of Morningstar, assesses environmental, social, and governance risks. Samsung Biologics was recognized for strengthening its environmental management through audits and hazardous waste recycling, enhancing social transparency via diversity policies and safety disclosures, and improving governance through ethical audits and board diversity goals.

This achievement follows other recent ESG milestones for the company, including an “A” rating from MSCI in September and a “Platinum” rating from EcoVadis in January. CEO John Rim stated that the result reflects the company’s ongoing efforts to advance its ESG risk management systems and maintain transparency for global stakeholders.